金融界1月7日消息,据CDE官网沟通交流公示,于1月7日收到乐普生物科技股份有限公司申请的“III类会议”,当前状态“处理中”。
根据《药物研发与技术审评沟通交流管理办法》(2020年第48号通告),沟通交流会议分为Ⅰ类、Ⅱ类和Ⅲ类会议,就关键阶段重大问题进行沟通交流,Ⅲ类会议一般安排在申请后75日内召开。
乐普生物科技股份有限公司,成立于2018年,位于上海市,是一家以从事医药制造业为主的企业。企业注册资本165944.4838万人民币,实缴资本149269.2648万人民币。
通过天眼查大数据分析,乐普生物科技股份有限公司共对外投资了8家企业,参与招投标项目19次,知识产权方面有商标信息10条,专利信息17条,此外企业还拥有行政许可55个。
主要股东信息显示,乐普生物科技股份有限公司由宁波厚德义民信息科技有限公司持股29.024%、乐普(北京)医疗器械股份有限公司持股15.097%、Miracogen Limited持股9.3106%、苏荣誉持股6.6993%、律元(上海)科技有限公司持股6.0294%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.